Davita (DVA) Rating Reiterated by Royal Bank of Canada
Davita (NYSE:DVA)‘s stock had its “hold” rating reiterated by equities researchers at Royal Bank of Canada in a research report issued to clients and investors on Wednesday, The Fly reports. They currently have a $65.00 price target on the stock. Royal Bank of Canada’s price objective would indicate a potential upside of 18.16% from the stock’s previous close.
Other research analysts have also issued reports about the company. ValuEngine upgraded Davita from a “hold” rating to a “buy” rating in a research note on Tuesday, October 9th. Zacks Investment Research upgraded Davita from a “hold” rating to a “buy” rating and set a $81.00 price objective for the company in a research note on Monday, October 8th. Deutsche Bank started coverage on Davita in a research note on Thursday, January 3rd. They set a “buy” rating and a $60.00 price objective for the company. TheStreet lowered Davita from a “b-” rating to a “c+” rating in a research note on Thursday, November 8th. Finally, Raymond James lowered Davita from a “strong-buy” rating to a “market perform” rating in a research note on Thursday, November 8th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $74.16.
Shares of DVA stock opened at $55.01 on Wednesday. The firm has a market capitalization of $8.95 billion, a P/E ratio of 16.57, a PEG ratio of 0.54 and a beta of 1.25. Davita has a one year low of $48.25 and a one year high of $80.71. The company has a debt-to-equity ratio of 2.09, a current ratio of 1.84 and a quick ratio of 1.82.
Several large investors have recently made changes to their positions in DVA. Honkamp Krueger Financial Services Inc. bought a new position in Davita in the third quarter valued at about $143,000. Atlas Capital Advisors LLC boosted its holdings in Davita by 247.9% in the third quarter. Atlas Capital Advisors LLC now owns 2,592 shares of the company’s stock valued at $188,000 after acquiring an additional 1,847 shares during the last quarter. Green Square Capital LLC bought a new position in Davita in the second quarter valued at about $208,000. Captrust Financial Advisors boosted its holdings in Davita by 96.8% in the third quarter. Captrust Financial Advisors now owns 3,050 shares of the company’s stock valued at $218,000 after acquiring an additional 1,500 shares during the last quarter. Finally, Seven Eight Capital LP bought a new position in Davita in the third quarter valued at about $219,000. Institutional investors own 85.66% of the company’s stock.
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Read More: Front-End Load
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.